

## WHO includes BD's MDR-TB assay in updated guidelines

14 April 2021 | News

The BD MAX<sup>™</sup> MDR-TB Assay is an in vitro diagnostic device with CE mark available in Europe and other countries around the world

BD (Becton, Dickinson and Company) has announced that its BD MAX<sup>™</sup> Molecular Multi-Drug Resistant Tuberculosis (MDR-TB) Assay was included in the moderate complexity automated NAAT class of molecular diagnostic technologies that were recognized for high diagnostic accuracy for tuberculosis testing by the World Health Organization (WHO) in advance of an update to its guidelines for TB diagnostic tests.

Laboratorians and clinicians can use the BD MAX<sup>™</sup> MDR-TB Assay to simultaneously detect bacteria that cause tuberculosis (TB) and determine if the bacteria contain mutations associated with resistance to two important first-line drugs, isoniazid (INH) and rifampicin (RIF), enhancing the information available to direct the optimal treatment for their patients.

The BD MAX<sup>™</sup> MDR-TB Assay is an in vitro diagnostic device with CE mark available in Europe and other countries around the world. The PCR-based molecular diagnostic test is an integrated diagnostic test intended to help in the detection and diagnosis of TB, and INH and RIF resistance in a single assay.

"BD is keenly focused on the fight against antimicrobial resistance and we believe the BD MAX<sup>™</sup> MDR-TB Assay will make a real impact on the detection of MDR-TB and better inform which treatment regimen to use for TB patients," saidDave Hickey, president of Life Sciences for BD. "This recognition by WHO is a significant milestone for this product and furthers BD's commitment in the fight to end TB. We look forward to WHO releasing its updated guidelines later this year."